Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is IOL Chemicals And Pharmaceuticals EV-to-EBITDA?
IOL Chemicals And PharmaceuticalsNSE:IOLCP +2.77%57 EV-to-EBITDA is 18.00 as of Jul. 15, 2026, which is 133% above its 10-year median of 7.72. GuruFocus rates NSE:IOLCP with a GF Score™ of 57/100 and a GF Value™ of ₹94.32 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 740 Drug Manufacturers companies, IOL Chemicals And Pharmaceuticals ranks worse than 63.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IOL Chemicals And Pharmaceuticals's enterprise value is ₹50,232 Mil.
IOL Chemicals And Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,791 Mil. Therefore, IOL Chemicals And Pharmaceuticals's EV-to-EBITDA for today is 18.00.
The historical rank and industry rank for IOL Chemicals And Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:IOLCP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.61 Med: 7.72 Max: 18
Current: 18
During the past 13 years, the highest EV-to-EBITDA of IOL Chemicals And Pharmaceuticals was 18.00. The lowest was 1.61. And the median was 7.72.
NSE:IOLCP's EV-to-EBITDA is ranked worse than 63.38% of 740
companies
in the Drug Manufacturers industry
Industry Median: 13.025
vs NSE:IOLCP: 18.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IOL Chemicals And Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
IOL Chemicals And Pharmaceuticals's share price for today is ₹173.78.
IOL Chemicals And Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, IOL Chemicals And Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IOL Chemicals And Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IOL Chemicals And Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IOL Chemicals And Pharmaceuticals's EV-to-EBITDA falls into.
IOL Chemicals And Pharmaceuticals's current Enterprise Value is ₹50,232 Mil.
IOL Chemicals And Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,791 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) has a EV-to-EBITDA of 18.00 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IOL Chemicals And Pharmaceuticals. This is 133% above median its historical median of 7.72. Over the past decade, IOL Chemicals And Pharmaceuticals' EV-to-EBITDA has ranged from 1.61 to 18.00. According to the industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #469 out of 740 companies in the Drug Manufacturers industry, placing it in the top 63.4%.
Is IOL Chemicals And Pharmaceuticals' EV-to-EBITDA too high?
IOL Chemicals And Pharmaceuticals' current EV-to-EBITDA of 18.00 is 133% above median its 10-year median of 7.72. Over the past 10 years, this metric has ranged from a low of 1.61 to a high of 18.00. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. IOL Chemicals And Pharmaceuticals' value of 18.00 is 38.2% above this industry median. Based on the distribution chart, IOL Chemicals And Pharmaceuticals ranks #469 out of 740 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, IOL Chemicals And Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IOL Chemicals And Pharmaceuticals' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #469 out of 740 companies for EV-to-EBITDA. This places IOL Chemicals And Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.03. IOL Chemicals And Pharmaceuticals' value of 18.00 is 38.2% above this benchmark. Historically, IOL Chemicals And Pharmaceuticals' own EV-to-EBITDA has ranged from 1.61 to 18.00 over the past decade. While the company's 10-year median is 7.72 vs. the industry median of 13.03, IOL Chemicals And Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IOL Chemicals And Pharmaceuticals's current EV-to-EBITDA of 18.00 is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IOL Chemicals And Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IOL Chemicals And Pharmaceuticals's current EV-to-EBITDA is 18.00, which is 133% above median its own 10-year median of 7.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IOL Chemicals And Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals (NSE:IOLCP) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹94.32, compared to a current price of ₹173.78 — trading 84.2% above its estimated fair value. The current EV-to-EBITDA is 18.00, which is 133% above median its 10-year median of 7.72 and 38.2% above the Drug Manufacturers industry median of 13.03. IOL Chemicals And Pharmaceuticals' overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For IOL Chemicals And Pharmaceuticals (NSE:IOLCP), the current EV-to-EBITDA is 18.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Overvalued in 2026?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹173.78 is trading 84.2% above its estimated GF Value™ of ₹94.32.
GuruFocus considers IOL Chemicals And Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:IOLCP:
EV-to-EBITDA: 18.00 (133% above median its 10-year median of 7.72)
GF Value™: ₹94.32 vs. price of ₹173.78 (84.2% above fair value)
Industry Position: 38.2% above the Drug Manufacturers median (#469 of 740)
No single metric tells the full story. See the NSE:IOLCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IOL Chemicals And Pharmaceuticals Business Description
IOL Chemicals And Pharmaceuticals Ltd is an India-based pharmaceutical company. The primary activity of the group is the manufacturing and sale of drugs and organic chemicals. The business activity is functioned through the Chemicals and Pharmaceutical segments. The Chemicals segment produces and sells chemicals such as Ethyl Acetate, Acetic Anhydride, Acetyl Chloride, Mono Chloro Acetic Acid, and Iso Butyl benzene, whereas the Pharmaceutical segment produces and sells various active pharmaceutical ingredients such as Ibuprofen, Metformin, Fenofibrate, Lamotrigine, and others. It derives prime revenue from the Pharmaceutical segment. Geographically, the group's products are sold in both the Indian and international markets.
57GF Score
Get the complete analysis for NSE:IOLCP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IOLCP has been successfully added to your 
